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Abstract
Background: Nasopharyngeal carcinoma (NPC) with lung metastasis alone has been reported as a relatively
favorable prognostic group, and combined modality treatment might be indicated for selected cases. However, the
prognostic factors determining survival of this group and the indication of combined therapy have not been
thoroughly studied.
Methods: We retrospectively reviewed 246 patients of NPC with lung metastasis(es) alone presented at diagnosis
or as the first failure after primary treatment from 1993 to 2008 in an academic tertiary hospital. Univariate and
multivariate survival analyses of post-metastasis survival (PMS) and overall survival (OS) were carried out to
determine the prognostic factors.
Results: The 3-year, 5-year, and 10-year of PMS and OS for the whole cohort were 34.3%, 17.0%, 8.6% and 67.8%,
45.4%, 18.5%, respectively. The median PMS (45.6 months vs. 23.7 months) and OS (73.7 months vs. 46.2 months) of
patients treated with combined therapy was significantly longer than that of those treated with chemotherapy
alone (P < 0.001). Age, disease-free interval (DFI) and treatment modality were evaluated as independent
prognostic factors of OS, while only age and treatment modality retain their independent significance in PMS
analysis. In stratified survival analysis, compared to chemotherapy alone, combined therapy could benefit the
patients with DFI > 1 year, but not those with DFI ≤ 1 year.
Conclusions: Age ≤ 45 years, DFI > 1 year, and the combined therapy were good prognostic factors for NPC
patients with lung metastasis(es) alone. The combination of local therapy and the basic chemotherapy should be
considered for these patients with DFI > 1 year.
Background
Nasopharyngeal carcinoma (NPC) is most prevalent in
southeastern Asia [1,2], the histology of which is almost
World Health Organization (WHO) types III (undifferen-
tiated) [3]. In contrast to other squamous cell carcinoma
of the head and neck, NPC is characterized by a high
tendency for metastatic dissemination [4,5]. About 5-8%
of NPC patients are present with distant metastasis(es) at
diagnosis, and 30 to 60% of locally advanced patients will
develop distant metastasis(es) and die of disseminated
disease [2,4,6]. NPC with distant metastasis makes a very
heterogeneous group, of which the post-metastatic survi-
val can vary considerably ranging from weeks to years
[7-9].
The lung is a one of the most common organ to which
distant metastasis can occur in NPC patients [10,11]. Hui
et al reported that, compared with other metastatic pat-
terns, those with lung metastasis(es) alone presented a
significantly better overall survival [7]. Others have
reported up to 60 months disease-free survival in patients
with solitary intrathoracic metastasis treated aggressively
with combined therapy [8,12,13]. Thus, we postulate that
i tm a yb ea s s o c i a t e dw i t hau n i q u eb i o l o g i cb e h a v i o ri n
NPC patients with lung metastasis(es) alone. However, to
our best knowledge, the mechanism behind the phenom-
enon and the precise predictive factors for intervention
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To date, the role of chemotherapy is well established
for metastatic NPC, but the objective response is still far
from satisfied [14-19]. Although several publications have
shown in small cohorts that NPC patients with lung
metastasis(es) alone may benefit from combined therapy,
no data exists in larger patient cohorts [8,20-22]. We set
out this retrospective study thought to add more evi-
dences to help define the predictive factors of this group
in a large cohort, and to facilitate the selection of the
appropriate group to receive combined modality treat-
ment for a better survival.
Methods
Patients
A database was prospectively established for the purpose
of this analysis. Between 1993 and 2008, a total of 246
NPC patients with lung metastasis(es) (either present at
diagnosis or at the first failure after receiving primary
treatment) in Sun Yat-Sen University Cancer Center
were consecutively enrolled. All the patients were patho-
logically confirmed NPC, and evaluated as complete
remission for local-regional disease after primary treat-
ment of radiotherapy with or without chemotherapy.
Lung metastasis(es) was routinely determined by chest
X-ray and/or computed tomography (CT). When both
X-ray and/or CT were insufficient to confirm lung
metastasis(es), the pathological confirmation by biopsy
was then carried out. Patients who have preexisting
malignant disease or a second primary tumor, or those
with extra-pulmonary metastases were excluded. The
study was approved by the medical ethics committee of
Sun Yat-Sen University Cancer Center.
The stages of the disease were classified according to the
Tumor-Node-Metastasis system (NCCN 2007). The differ-
entiation status and histotype of the disease were classified
according to the World Health Organization (WHO) clas-
sification for NPC. The characteristics of the 246 NPC
patients enrolled in the study are shown in Table 1.
Treatments
For patients presented with lung metastasis(es) at diagno-
sis (M1), 6 cycles of chemotherapy with Cisplatin/5-fluor-
ouracil (PF) regimen were administered before concurrent
chemoradiotherapy. The PF chemotherapy regimen con-
sisted of 20 to 30 mg/m
2 cisplatin intravenous bolus on
days 1 to 3 and 800 to 1,000 mg/m
2/24 hours continuous
intravenous infusion of 5-fluorouracil on days 1 to 4 of
each cycle, repeated every 21 days. For those with M0
stage, radical radiotherapy or concurrent chemoradiother-
apy with the Cisplatin-based regimen were performed for
early stage or locally advanced NPC patients, respectively.
During the treatments, new metastatic lesions were found
in none of the patients, and all of them received external
beam radiotherapy by a 6 MV linear accelerator. All
patients had planning computerized tomography of the
head and neck performed with patient in the treatment
Table 1 Characteristics of 246 NPC patients with lung
metastasis(es) alone at diagnosis or the first failure
Characteristics No. of patients (%)
Age (years)
a
≤ 45 130 (52.8)
> 45 116 (47.2)
Gender
Male 196 (79.7)
Female 50 (20.3)
Histology
WHO type I 3 (1.2)
WHO type II 7 (2.8)
WHO type III 236 (96.0)
EBV VCA-lgA
b
≤ 320:1
c 100 (40.7)
> 320:1 70 (28.5)
EBV EA-lgA
b
≤ 40:1
d 112 (45.5)
> 40:1 58 (23.6)
UICC T classification
T1-2 97 (39.4)
T3-4 149 (60.6)
UICC N classification
N0 41 (16.7)
N1-3 205 (83.3)
UICC M classification
M0 201 (81.7)
M1 45 (18.3)
Lung metastasis
DFI (years)
≤ 1 92 (37.4)
1-3 86 (35.0)
> 3 68 (27.6)
Metastasis site
Unilateral 118 (48.0)
Bilateral 128 (52.0)
Metastasis number
Solitary 82 (33.3)
Multiple 164 (66.7)
Metastasis size (cm)
e
≤ 2 147 (59.8)
> 2 99 (40.2)
Abbreviation: NPC, nasopharyngeal carcinoma; WHO, World Health
Organization; UICC, International Union Against Cancer; DFI, disease-free
interval.
a Median age;
b Data was available for 170 cases;
c Median EBV VCA lgA;
d Median EBV EA lgA;
e Median metastasis size.
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treatment planning was obtained before the initiation of
radiotherapy. A dose of 68-70 Gy/6.5-7 weeks was nor-
mally given to the primary tumor. A does of 64-66 Gy/6-7
weeks to the involved neck nodes, whereas the does for
node-negative neck was 50 Gy/5-5.5 weeks. Therapeutic
efficacy was assessed 3-6 months after the primary treat-
ment, according to the Response Evaluation Criteria in
Solid Tumors (RECIST) criteria.
The patients were followed up in the out-patient clinics,
where diagnostic examinations consisting of nasopharyn-
geal and neck magnetic resonance imaging (MRI), chest
x-ray and/or CT, abdominal ultrasonography and bone
scan were performed every 3-6 months for the first 3 years
and finally annually thereafter to detect local recurrence
and/or metastasis. For those present with lung metastasis
(es) alone as the first failure, 4-6 cycles of palliative che-
motherapy with DDP based regimen was administered.
Local therapies such as surgery or radiotherapy served as
options for those still with metastatic lesions limited in
lung after chemotherapy.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 pack-
age (SPSS Standard version 13.0, SPSS Inc, Chicago, IL).
Chi-square test was used to compare the difference of
categorical variables. Disease-free interval (DFI) was cal-
culated from the completion of initial treatment to the
time when lung metastasis(es) was identified. Overall sur-
vival (OS) or post-metastasis survival (PMS) was defined
as from the date of completing the initial treatment or
t h ed a t eo fl u n gm e t a s t a s i s ( es) identified to the date of
death or the last follow-up, respectively. The survival
curves were calculated by the Kaplan-Meier method and
compared using the log-rank test. Multivariate survival
analysis was performed on all parameters that were
found significant on univariate analysis using the Cox
regression model. P values < 0.05 were considered
significant.
Results
Patients’ characteristics and treatments
The clinical and pathological characteristics of the 246
NPC patients with lung metastasis(es) alone in this
study are listed in Table 1. Among 246 patients, 45
patients were diagnosed with NPC along with lung
metastasis(es) while the other 201 cases developed lung
metastasis(es) after primary treatment. Single radiother-
apy, concurrent chemoradiotherapy and 6 cycles of che-
motherapy followed by concurrent chemoradiotherapy
were performed in 55, 146 and 45 cases, respectively.
Each of the patients had a complete remission (CR) for
nasopharynx and the involved cervical nodes after the
primary treatment.
After the lung metastasis(es), all the patients received
at least 4-6 cycles of chemotherapy, 126 cases of which
received ≤ 6 cycles, the other 120 cases received > 6
cycles. CR for the metastatic lung lesions evaluated by
CT was obtained in 4.9% (12/246) of the patients after
chemotherapy; for those CR was not obtained, palliative
metastasectomy or radiotherapy was served as an
option, and was performed in 27 and 37 of the 234
patients. Local-regional recurrence along with or after
lung metastasis(es) was observed in 31 patients out of
the total 246 cases. The 23 cases with local nasopharyn-
geal recurrence had palliative radiotherapy and the other
8 cases with regional lymph nodes recurrence received
regional neck lymph nodes dissection.
The treatment of lung metastasis(es) and/or local
recurrence were tolerated. The Common Terminology
Criteria for Adverse Events (CTCAE) was used to eval-
uate the acute toxicity. There were no treatment-
related deaths and no grade 4 toxicity. The acute toxi-
cities were listed in Table 2. Twelve patients experi-
enced long-term toxicitiess u c ha sx e r o s t o m i a( s i x
patients), mucositis (three patients), radiation pneumo-
nitis (two patients) and sensorineural hearing loss (one
patient).
Table 2 Grade 3/4 acute toxicity according to CTCAE.
Acute toxicity No. of patients %
Evaluable patients 198
Leukopenia
Grade 3 65 32.8
Grade 4 0 0
Thrombocytopenia
Grade 3 19 9.6
Grade 4 0 0
Anemia
Grade 3 30 15.2
Grade 4 0 0
Vomitting
Grade 3 22 11.1
Grade 4 0 0
Mucositis
Grade 3 25 12.6
Grade 4 0 0
Diarrhea
Grade 3 6 3.0
Grade 4 0 0
Stomatitis
Grade 3 6 3.0
Grade 4 0 0
Renal toxicity
Grade 3 0 0
Grade 4 0 0
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.
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The mean and median DFI for the primary M0 cases
were 34.4 months and 22.7 months, respectively, ranging
from 2.3 months to 184.9 months. The mean and med-
ian DFI for the primary M1 cases were calculated as 0.
In total, there are 92, 86, and 68 cases with a DFI less
than 1 year, 1-3 years and greater than 3 years, respec-
tively. As shown in Table 3, patients with age less than
45 years, T1-2 and N0 classification seems to have a
longer DFI before lung metastasis(es) developed than
those with age greater than 45 years, T3-4 and N1-3
classification.
Survival status
The median observation period was 45.8 months (range,
3.2-218.7 months) for the whole cohort, and 170 deaths
were observed. The 3-year, 5-year and 10-year OS and
PMS for the entire cohort of patients were 67.8%, 45.4%,
18.5% and 34.3%, 17.0%, 8.6%, respectively (Figure 1A and
1B). The median survival time of patients with M0 classifi-
cation compared with M1 classification was significantly
longer in OS (61.7 months vs. 26.8 months, P < 0.001) but
similar in PMS (26.2 months vs. 26.8 months, P = 0.758,
Figure 1C and 1D). The median OS and PMS for patients
treated with combined therapy and chemotherapy alone
were 73.7 months, 46.2 months (P < 0.001) and 45.6
months, 23.7 months (P < 0.001), respectively (Figure 1E
and 1F).
Prognostic factors of survival
In univariate analysis, age, EBV VCA-lgA, DFI, metastasis
site, metastasis number, local-regional recurrence, treat-
ment modality and chemotherapy effect were evaluated
as predicting factors for PMS; while only age and treat-
ment modality retained their significance in multivariate
analysis (Table 4). Similarly, age, T classification, N clas-
sification, M classification, DFI, metastasis site, metastasis
number, metastasis size and treatment modality were
evaluated as prognostic factors for OS; while only age,
DFI and treatment modality retained their significance in
multivariate analysis (Table 4).
Since age and DFI together with treatment modality
were found to be important prognostic factors for patient
survival, we next performed stratified analysis according to
age and DFI to find out which subgroups of NPC patients
with lung metastasis(es) alone will benefit from the com-
bined therapy modality. The results showed that patients
treated with combined therapy presented a better survival
than those treated only with chemotherapy in both age
less than 45 years and age greater than 45 years subgroups
(Table 5). Treatment modality could also stratify the out-
come of patients with DFI greater than 1 year, but not
those with DFI less than 1 year (Table 5, Figure 2).
Discussion
Although the prognosis of metastatic NPC is still quite
poor, it has been well accepted that the survival of meta-
static NPC can be highly variable and long-term survival
is possible in some patients [7-9,17,23,24]. Particularly,
NPC patients with lung metastasis(es) alone were
reported as a distinctive group with a good prognosis
compared with other type of metastasis [7,8]. Thus, the
identification of prognostic factors of this group will be
of great importance from both a therapeutic and research
point of view. In this study, we presented the long-term
outcome and prognostic indicators of survival in a large
cohort of NPC patients with lung metastasis(es) alone.
The 3-year OS and PMS reported in metastatic NPC
patients with different series were less than 40% and 20%,
respectively [9]. In the present study, we reported a much
better prognosis in 246 NPC patients with lung metastasis
(es) alone, with a 3-year OS of 67.8% and a 3-year PMS of
34.3%. Our results concurred closely with another study of
lung metastasis of NPC in Hong Kong that NPC patients
with lung metastasis(es) alone (n = 41) appeared to have a
distinctively better prognosis, with a hazards ratio (HR) of
0.41 compared with other types of metastasis(es) [7]. In
other studies, intrathoracic metastasis(es) (lung and/or
Table 3 Association between clinical characteristics and
DFI in 246 NPC patients with lung metastasis(es) alone at
diagnosis or the first failure
Disease-free interval
Characteristics ≤ 1 year 1-3 years ≥ 3 years P
a
Age (years) 0.018
≤ 45 39 (30.0) 47 (36.2) 44 (33.8)
> 45 53 (45.7) 39 (33.6) 24 (20.7)
Gender 0.701
Male 75 (38.3) 66 (33.6) 55 (28.1)
Female 17 (34.0) 20 (40.0) 13 (26.0)
EBV VCA-lgA
b 0.624
≤ 320:1
c 35 (35.0) 37 (37.0) 28 (28.0)
>320:1 30 (42.9) 22 (31.4) 18 (25.7)
EBV EA-lgA
b 0.826
≤ 40:1
d 42 (37.5) 38 (33.9) 32 (28.6)
> 40:1 23 (39.7) 21 (36.2) 14 (24.1)
UICC T classification 0.001
T1-2 25 (25.8) 33 (34.0) 39 (40.2)
T3-4 67 (45.0) 53 (35.5) 29 (19.5)
UICC N classification 0.012
N0 10 (24.4) 12 (29.3) 19 (46.3)
N1-3 82 (40.0) 74 (36.1) 49 (23.9)
Abbreviation: NPC, nasopharyngeal carcinoma; DFI, disease-free interval; UICC,
International Union Against Cancer.
a Chi-square test;
b Data was available for 170 cases;
c Median EBV VCA lgA;
d Median EBV EA lgA.
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factor in metastatic NPC [8,20,21]. However, to our
knowledge, no literature has identified the precise predic-
tive factors for the prognosis in this specific group.
It was demonstrated in our study that young age (≤ 45
years), long DFI (> 1 year), unilateral metastasis, solitary
metastasis and combined therapy were good prognostic
factors in terms of both OS and PMS based on
Figure 1 Survival analysis according to different groups. Overall survival (OS) and post-metastasis survival (PMS) curves for the whole cohort
(A and B) and stratified by M classification (C and D) and treatment modalities (E and F).
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Page 5 of 9Table 4 Prognostic variables of 246 NPC patients with lung metastasis(es) alone at diagnosis or the first failure
Post-metastasis survival Overall survivall
Variables Univariate Analysis P
a Multivariate Analysis P
a Univariate Analysis P
a Multivariate Analysis P
a
Age 1.485 (1.097-2.010) 0.010 1.537 (1.038-2.277) 0.032 1.734 (1.277-2.355) < 0.001 1.424 (1.027-1.974) 0.034
Sex 1.018 (0.712-1.458) 0.921 - - 1.022 (0.714-1.463) 0.905 - -
T classification 1.298 (0.948-1.778) 0.104 - - 1.774 (1.281-2.456) 0.001 1.326 (0.936-1.876) 0.112
N classification 1.224 (0.809-1.852) 0.339 - - 1.758 (1.150-2.688) 0.009 1.395 (0.905-2.150) 0.131
M classification 0.938 (0.625-1.408) 0.758 - - 3.010 (1.965-4.612) < 0.001 1.290 (0.766-2.172) 0.338
EBV VCA-lgA 1.490 (1.033-2.148) 0.033 1.342 (0.920-1.958) 0.127 1.348 (0.935-1.942) 0.110 - -
EBV EA-lgA 1.171 (0.803-1.710) 0.412 - - 1.199 (0.820-1.753) 0.349 - -
DFI 0.818 (0.676-0.991) 0.040 1.019 (0.796-1.304) 0.881 0.326 (0.263-0.404) < 0.001 0.379 (0.294-0.490) < 0.001
Metastasis site 1.846 (1.357-2.512) < 0.001 1.295 (0.779-2.153) 0.319 1.964 (1.439-2.682) < 0.001 1.561 (0.967-2.520) 0.068
Metastasis number 1.813 (1.295-2.539) 0.001 1.274 (0.705-2.301) 0.422 1.970 (1.403-2.768) < 0.001 1.284 (0.761-2.097) 0.365
Metastasis size 0.952 (0.699-1.296) 0.754 - - 0.689 (0.505-0.941) 0.019 0.922 (0.664-1.281) 0.629
Recurrence 1.785 (1.125-2.832) 0.014 1.429 (0.778-2.625) 0.250 1.197 (0.755-1.896) 0.444 - -
Treatment modality
b 0.440 (0.302-0.641) < 0.001 0.583 (0.355-0.960) 0.034 0.454 (0.321-0.660) < 0.001 0.566 (0.374-0.857) 0.007
Chemotherapy cycle
c 0.828 (0.612-1.122) 0.828 - - 1.143 (0.842-1.552) 0.392 - -
-Chemotherapy effect
d 2.305 (1.016-5.228) 0.046 1.243 (0.511-3.026) 0.632 1.603 (0.708-3.627) 0.258 - -
Abbreviation: NPC, nasopharyngeal carcinoma; DFI, disease-free interval.
a Cox proportional hazards analysis.
b Chemotherapy alone vs. combined therapy;
c chemotherapy cycle < 6 vs. chemotherapy cycle ≥ 6;
d Complete remission vs. non-complete remission.
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9univariate survival analysis, while only young age, long
DFI and combined therapy were found to be indepen-
dent good prognostic factors of OS according to multi-
variate analysis. These factors have also been indicated
in other studies as good prognosis in patients with lung
metastasis(es) from head and neck cancers [4,11,25,26].
For young age, we cannot explain clearly why it is a
good prognostic factor, but it may be related to the sig-
nificant association between young age and long DFI
found in the present study. In another hand, young
patients usually have better performance status to toler-
ate the side effect of aggressive combined therapy, and
react positively towards the treatment than old patients,
and thus they are more likely to accept the treatment
after the discovery of lung metastasis(es) than elderly
patients.
DFI has long been identified as an important prognos-
tic factor for patient outcome, but the significant cutoff
points of DFI are still uncertain according to the litera-
tures [4,8,11,27-29]. In NPC, Teo et al reported that the
OS of patients presenting with distant metastasis(es) abi-
nitio (M1, DFI = 0) is much worse than those develop-
ing distant metastasis(es) after primary radiotherapy
(M0, DFI > 0) [8]. In our study, DFI = 0 (M1) was also
found to a poor prognostic factor of OS of NPC patients
in univariate analysis, but there was no difference of
PMS between DFI = 0 months (M1) and DFI > 0
months (M0) groups. Another reported cutoff of DFI <
6 months, which was identified by Ong et al as an inde-
pendent prognostic factor of PMS in metastatic NPC;
while in another study conducted by Khanfir et al, no
difference of PMS between groups with DFI ≤ 6 months
and DFI > 6 months was observed [4,11]. It’sb e l i e v e d
that different types of metastatic NPC might correspond
with different significant cutoff points of DFI, which
might partly contribute the variances of DFI cutoff
points reported in the literatures. In our study, we pro-
posed that DFI ≤ 1 year, 1-3 years and > 3 years were
the proper cutoff values to distinguish both the OS and
PMS in NPC patients with lung metastasis(es) alone.
Patients with young age (≤ 45 years), early T classifica-
tion, and without lymph node metastasis would be likely
to have longer DFI.
Treatment modality is another important independent
prognostic factor in our study. We demonstrated that,
compared to single chemotherapy, combined therapy
improved both the OS and PMS for NPC patients with
lung metastasis(es) alone. Geara et al reported similar
results in 103 metastatic NPC patients who treated with
radiotherapy and chemotherapy (2 yeras-OS, 45%) for
their metastases had a significantly better survival than
those received no treatment (2 years-OS, 14%) or single
chemotherapy (2 years-OS, 18%, P = 0.001) [22]. In addi-
tion, some long-term survivors aggressively treated with
pulmonary metastasectomy in combination with che-
motherapy were also reported in NPC patients with
intrathoracic metastasis(es) alone [10,12,13,20,28-30].
Collectively, these data suggests an indication for com-
bined therapy in selected metastatic NPC patients. Thus,
it seems necessary to further evaluate which subgroup of
patients would benefit from it. In our stratified survival
analysis, treatment modality was found to have improved
the outcome of patients with DFI greater than 1 year, but
not those with DFI less than 1 year.
Table 5 Stratified analysis in 246 NPC patients with lung metastasis(es) alone at diagnosis or the first failure
PMS OS
Variables Cases HR (95% CI) P
a HR (95% CI) P
a
Age ≤ 45 years 0.004 0.005
Chemo alone 90 1 1
Chemo+local 40 0.484 (0.293-0.798) 0.485 (0.292-0.805)
Age > 45 years 0.005 0.006
Chemo alone 92 1 1
Chemo+local 24 0.434 (0.242-0.779) 0.451 (0.257-0.792)
DFI < 1 year 0.283 0.571
Chemo alone 78 1 1
Chemo+local 14 0.676 (0.332-1.380) 0.814 (0.400-1.656)
DFI = 1~3 years 0.008 0.005
Chemo alone 59 1 1
Chemo+local 27 0.460 (0.260-0.815) 0.429 (0.239-0.770)
DFI > 3 years 0.006 0.006
Chemo alone 45 1 1
Chemo+local 23 0.353 (0.168-0.739) 0.342 (0.160-0.730)
Abbreviation: NPC, nasopharyngeal carcinoma; PMS, post-metastasis survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; DFI, disease-
free interval.
a Cox proportional hazards analysis.
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is a retrospective study, relied exclusively on a single-
institutional database. A larger scale, prospective, multi-
center study is needed to confirm our results.
Conclusions
In conclusion, our study is the first retrospective study
in southern China to identify the prognostic indicators
of long-term survival in a large group of NPC patients
with lung metastasis(es) alone. Based on our results, age
less than 45 years, DFI greater than 1 year and the com-
bined modality treatment were good prognostic factors.
The combined therapy should be highly considered for
lung metastatic NPC patient with DFI greater than
1 year to achieve better survival.
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